Latest Breaking News On - Trastuzumab biosimilar - Page 1 : comparemela.com

EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.

United statesEirgenix incMinistry of healthEuropean unionEuropean commissionNational health insurance administrationRgenix incTaiwan foodDrug administrationHer2 positiveTrastuzumab biosimilar

Trastuzumab Biosimilar Use Significantly Increasing in the US

Analysis shows the rate of use with the originator biologic has decreased from 90% in 2016, to 19% in 2021.

United statesHerceptin biosimilarMai xiaodanTrastuzumab biosimilarBiologics biosimilars collective intelligence consortiumHarvard pilgrim health care instituteDrug administrationInternational conference on pharmacoepidemiologyHarvard medical schoolInternational conferenceTherapeutic risk managementAnnual meetingBiosimilars collective intelligence consortiumThird herceptinPublished januaryBreast cancer

Stocks in news: LTIMindtree, Mankind Pharma, RBL Bank, Suzlon Energy, Aurobindo Pharma

Mankind Pharma, a recent entrant to the stock exchanges, has been included to several Nifty indices including Nifty500, Nifty Midcap150, Nifty Midcap100 and Nifty200.

Sunil samdaniTrastuzumab biosimilarAurobindo pharmaBoard of suzlon energyTechnology gmbh switzerlandDalal streetNifty midcapGeneral electric technology gmbhSuzlon energyCurateq biologicsGenus power infrastructure

CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product

CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Trastuzumab biosimilarSatakarni makkapatiAurobindo pharmaCurateq biologics privateCurateq biologicsPharma limitedCurateq biologics private limitedAurobindo pharma limited

FDA Accepts BLA for Trastuzumab Biosimilar in HER2+ Breast Cancer, Gastric/GEJ Cancer

The FDA has accepted a biologics license application for the HLX02, a proposed trastuzumab biosimilar, as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Chrys kokinoShanghai henlius biotech incEuropean unionEuropean commissionAccord biopharmaShanghai henlius biotechNational medical products administrationTrastuzumab biosimilarHer2 overexpressing breast cancerHer2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinomaBiologics license application